The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
The submission is supported by results from the Phase 3b APEX study
Subscribe To Our Newsletter & Stay Updated